Background-Improving functional status and quality of life are important goals of treatment for patients with severe aortic stenosis. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a heart failure health status measure and has been used in studies of patients with aortic stenosis. However, its psychometric properties have not yet been evaluated in these patients. Methods and Results-We analyzed data from 955 patients, enrolled in the PARTNER trial of transcatheter aortic valve replacement, to evaluate the reliability, responsiveness, validity, and prognostic importance of the KCCQ in patients with severe aortic stenosis. The KCCQ was administered at baseline and at 1, 6, and 12 months after randomization to medical therapy, transcatheter aortic valve replacement, or surgical valve replacement. Among clinically stable patients, there were only small changes in the KCCQ domain scores over time (mean differences 0.1-4.2 points), and the intraclass correlation coefficients showed good agreement between paired assessments (0.65-0.76). However, the domain scores of patients who underwent transcatheter aortic valve replacement showed large changes after treatment (mean differences 13-30 points). Construct validity was demonstrated by comparing each domain against a relevant reference measure (Spearman correlations 0.46-0.69). Finally, among 157 patients randomized to medical management, lower KCCQ overall summary scores at baseline were strongly associated with an increased risk of mortality during the following 12 months. Conclusions-The KCCQ is a highly reliable, responsive, and valid measure of symptoms, functional status, and quality of life in patients with severe, symptomatic aortic stenosis. (Circ Heart Fail. 2013;6:61-67.)
A ortic stenosis (AS) is prevalent among the elderly and, once symptoms develop, is associated with considerable risk of morbidity and mortality. Although surgical aortic valve replacement (AVR) has been considered the gold standard therapy for patients with symptomatic AS, transcatheter AVR (TAVR) has recently emerged as a less invasive therapeutic option. Moreover, TAVR has been shown to have a substantial mortality advantage over medical therapy in patients considered to be at high-risk for surgical AVR 1,2 because many of these patients who are very elderly and with multiple comorbid conditions, improvements in symptoms and quality of life may be more important goals of therapy. 3, 4 As such, a thorough understanding of health status outcomes should be an integral part of any study examining treatment options for severe AS, including TAVR. 5 
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Currently, there are no instruments designed specifically for the assessment of health status and quality of life among patients with AS. Previous studies have used either generic health status measures, such as Medical Outcomes Study Short-Form 36 (SF-36) or EuroQol-5D, or relatively crude scales, such as the New York Heart Association (NYHA) classification scheme. [6] [7] [8] However, these scales have several limitations, including limited responsiveness to clinically important changes and reliance on external assessors (rather than the patients themselves). Although patients with severe AS may experience angina or syncope as their major presenting symptom, heart failure symptoms are predominant among patients presenting for AVR. 9, 10 As such, use of a heartfailure-specific instrument has been suggested as a potentially useful approach for this population. 5 The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific instrument originally designed to describe and monitor health status in patients with heart failure. 11 The KCCQ has been extensively tested for reliability and validity in various heart failure populations [11] [12] [13] and has been shown to predict mortality 14 and healthcare costs 15 in such patients. However, its psychometric properties have not been evaluated in patients with AS. We, therefore, designed a secondary analysis of a series of clinical trials to assess the reliability, responsiveness, validity, and prognostic importance of KCCQ among patients with severe AS undergoing a range of therapeutic approaches as part of the Placement of Aortic Transcatheter Valves (PARTNER) trial.
Methods

Patient Population
Patients for our validation study were drawn from the PARTNER trial of patients with severe symptomatic AS who were being considered as potential candidates for TAVR. Full details of the study inclusion and exclusion criteria have been described previously. 1, 16 Enrolled patients were required to have severe AS (defined as an aortic valve area of <0.8 cm 2 with either a mean aortic valve gradient of ≥40 mm Hg or a peak aortic-jet velocity of ≥4.0 m/s); NYHA class II, III, or IV heart failure symptoms; and high surgical risk based on the Society for Thoracic Surgeons (STS) risk score. On the basis of the assessment of 2 cardiac surgeons, eligible patients were classified as either high-risk but suitable for surgical AVR (Cohort A), 16 or ineligible for cardiac surgery because of coexisting medical conditions associated with a predicted probability of death or permanent disability ≥50% (Cohort B).
1 Cohort A patients were randomized to undergo either surgical AVR or TAVR, whereas Cohort B patients were randomized to TAVR versus medical therapy. The study was approved by the institutional review board at each participating site, and all patients provided written informed consent.
Health Status and Clinical Assessment
Patients were assessed for clinical factors and health status at baseline and at 1, 6, and 12 months after randomization. Health status, which includes symptoms, functional status, and quality of life, was evaluated with the KCCQ, SF-12 Health Survey, and the EuroQol-5D. 17 Linguistically and culturally validated translations of the questionnaires were provided to non-English speakers. Disease-specific health status was assessed with the KCCQ, 11 a 23-item self-administered questionnaire that addresses specific health domains pertaining to heart failure: physical limitation, symptoms, quality of life, social limitation, symptom stability, and self-efficacy-the first 4 of which are combined into an overall summary scale. Values for the domains range from 0 to 100 with higher scores indicating lower symptom burden and better quality of life. The self-efficacy domain is designed to assess whether or not a patient feels they have the knowledge and skills to manage their heart failure as an outpatient. Because patients with severe AS often have symptoms and hospitalizations that are unrelated to their knowledge of their disease, the self-efficacy domain of the KCCQ does not apply to patients with AS and thus was excluded from these analyses. The symptom stability domain uses a single question to assess the change in the patient's heart failure symptoms during the past 2 weeks. As such, longitudinal analyses of this domain are difficult to interpret (ie, a change of a change). This domain was thus excluded from the reliability and responsiveness analyses.
Generic health status was assessed with SF-12 and EuroQol-5D. The SF-12 is a reliable and valid measure of generic health status that provides summary component scales for overall physical and mental components summary health. 18 Scores are standardized using norm-based methods to generate a mean of 50 and a SD of 10, with higher scores indicating better health status. 19 The EuroQol-5D is a 5-item instrument that assesses specific domains of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 20 Responses to these questions were converted to utility weights according to an algorithm developed for the US population. 21, 22 In addition to patient-reported health status, patients were assessed for NYHA functional class and the distance covered during a 6-minute walk test at baseline and at each of the follow-up timepoints.
Statistical Analysis
Determining Questionnaire Reliability
Internal consistency of the KCCQ domains was assessed using Cronbach α. All patients at baseline were included in this analysis (n=940). Values of the Cronbach α statistic range from 0 to 1 and reflect the consistency of different items within each individual domain. In general, α≥0.9 indicates excellent consistency, 0.9>α≥0.8 is quite good, 0.8>α≥0.7 is acceptable, 0.7>α≥0.6 is questionable, and 0.6>α is poor. 23 To test the instrument's test-retest reproducibility, we first identified a cohort that was clinically stable throughout the period of observation. This cohort included patients who were 12 months post-TAVR, had no hospitalizations in the past 6 months, and had no change in NYHA functional class from 6 to 12 months. A total of 152 patients met the inclusion criteria for the stable cohort. Domain scores at 6 and 12 months were then compared using paired t tests. Reproducibility was further examined with the intraclass correlation coefficient, 24 which is the ratio of between-groups variance:total variance. The intraclass correlation coefficient ranges from 0 to 1 with higher scores indicating increased test-retest reliability. In general, an intraclass correlation coefficient 0 to 0.2 indicates poor agreement, 0.3 to 0.4 fair agreement, 0.5 to 0.6 moderate agreement, 0.7 to 0.8 strong agreement, and >0.8 excellent agreement.
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Determining Questionnaire Responsiveness
The responsiveness of the KCCQ domains to a clinical change was first assessed among patients who underwent TAVR and were alive at 1 month after the procedure (n=419). Scores at baseline and 1 month were compared using paired t tests. Cohen d effect size, 26 which quantifies the magnitude of change relative to baseline variation, was also used to assess the responsiveness of the questionnaire to clinical change. In general, an effect size of 0.2 to 0.3 indicates a small effect, ≈0.5 is a medium effect, and ≥0.8 is a large effect. 27 To examine the sensitivity of the KCCQ to clinically relevant changes and its ability to discriminate between different levels of change, we calculated the change in domain scores for all patients from baseline to 1 month (n=761) stratified by their change in NYHA class during the same period and examined the relation between the change in domain scores versus the change in NYHA class using a linear trend test.
Determining Questionnaire Validity
The validity of the different domains was tested by comparing the domains with other measures that quantify similar concepts. For the symptom stability domain, we compared 2 cohorts of patients at 1 month: a stable cohort of 15 patients who were medically managed and had no interval hospitalizations and no change in NYHA class from baseline to 1 month; and an unstable cohort of 347 patients who underwent TAVR and had an improvement in NYHA class from baseline to 1 month. Symptom stability scores at 1 month were compared between the 2 groups using an independent t test.
For all other domains, the analytic cohort comprised all patients alive at 6 months after randomization (n=739). For the KCCQ physical limitations domain, we examined the correlation with the 6-minute walk test, the SF-12 physical components summary, and NYHA functional class. For the KCCQ symptoms domain and the overall summary score, we examined their correlations with NYHA functional class. Finally, we examined the correlations between both the KCCQ quality of life and social limitations scales and the SF-12 mental components summary. The criterion standards chosen for these comparisons closely mirror those used in the original validation of the KCCQ. 11 Spearman rank correlation coefficients were used to test all correlations.
Prognostic Importance
The association between the KCCQ overall summary score and survival was examined among patients who were randomized to medical therapy alone (n=157). We first compared the mean baseline scores between patients who died (n=77) and those who survived the 12 months after randomization (n=80) using independent t tests.
Cox proportional hazard regression was used to evaluate the association between baseline scores as a continuous variable (scaled per 10 points) and 12-month mortality, adjusting for the STS risk score which incorporates multiple prognostically important demographic and clinical factors (eg, age, sex, multiple comorbidities, cardiac structure, and function; Table I in the online-only Data Supplement) into a mortality risk estimate. Finally, we examined the relationship between the KCCQ overall summary scale as a categorical variable (0-25, 26-50, and >50) 14 and 12-month survival using Kaplan-Meier survival curves and the log-rank test. Cox regression was used to evaluate the association of KCCQ scores as a categorical variable (reference group: scores >50) with 12-month mortality after adjusting for the STS mortality risk score.
All analyses were conducted using SAS v9.2 (SAS Institute, Inc, Cary, NC), and statistical significance was determined by a 2-sided probability value of <0.05.
Results
Patient Population
The overall patient population included 955 patients with severe AS (mean AVA=0.64 cm 2 ). The mean age of the population was 84 years, 46% were female, the mean left ventricular ejection fraction was 53%, and 94% had NYHA class III or IV heart failure symptoms. As participants in the PART-NER trial, a total of 157 patients were randomized to medical therapy, 498 were assigned to TAVR, and 300 were assigned to surgical AVR ( Table 1) . Descriptions of patients included in each of the analyses and the tests used to assess each of the psychometric properties are shown in Table 2 and Table II in the online-only Data Supplement.
Reliability of the KCCQ
The results of the internal consistency analysis of the domains of the KCCQ are shown in Table 3 . The quality of life domain demonstrated acceptable consistency (α=0.72), whereas all other domains showed good or excellent consistency (α>0.8). The reproducibility of the KCCQ among 159 patients who were clinically stable between assessments is shown in Table 4 .
Serial assessments were similar between 6 and 12 months for all domains except the physical limitations domain, in which the mean within-patient change in scores decreased by 4.2 points (95% confidence interval, 0.9-7.4; P=0.013), although the intraclass correlation coefficient was high suggesting greater intersubject than within-subject variability. In fact, the intraclass correlation coefficient indicated moderate-to-strong agreement between the 2 assessments for all domains, supporting the reproducibility of the KCCQ in stable patients. 
Responsiveness of the KCCQ
Among patients who underwent treatment for their AS with TAVR, there were dramatic differences in the KCCQ scores before and after treatment ( Table 5 ). The symptoms, quality of life, and overall summary domains of the KCCQ showed large effect sizes, with the physical limitations and social limitations domains showing moderate effect sizes. When all patients alive at 1 month were stratified by change in NYHA class from baseline, the KCCQ demonstrated excellent discriminatory ability (Table 6 ). There was little difference in the change in KCCQ between those with a class II and class III decrease in NYHA, possibly reflecting the coarseness of the NYHA measurement.
Validity of the KCCQ
The results of correlation analyses between the KCCQ domains and relevant criterion standards (based on 6-month results for all scales) are summarized in Table 7 . The physical limitations domain was significantly correlated with measures of functional status, including the 6-minute walk test (r=0.46), the SF-12 physical components summary (r=0.69), and NYHA class (r=−0.49; P<0.0001 for all). The quality of life domain was highly correlated with measures of generic health status including the SF-12 physical (r=0.52) and mental components (r=0.50), as well as EuroQol-5D derived uses (r=0.52; P<0.0001 for all). The social limitations domain was highly correlated with the SF-12 mental component (r=0.50; P<0.0001). The KCCQ symptom scale and overall summary score were highly correlated with NYHA class (r=−0.50 and −0.53, respectively; P<0.0001 for both; Figure 1) 
Prognostic Importance
During the 12 months after randomization, 77 of the 157 patients (49%) who were randomized to medical management died. At baseline, mean scores on the KCCQ overall summary scale of those patients who died were significantly lower than those who were alive at 12 months (28.2 versus 41.0, P<0.0001). In a Cox proportional hazards model adjusted for STS mortality risk score, every 10 point decline in the KCCQ overall summary scale at baseline was associated with a 34% greater hazard of dying during the following 12 months (hazard ratio, 1.34; 95% confidence interval, 1.17-1.54; P<0.0001). Similar findings were noted in categorical analyses in which there was a strong association between ranges of the baseline KCCQ summary scale and 12-month survival ( Figure 2 ). Compared with patients who had baseline scores >50, patients with scores of ≤25 faced a nearly 4-fold increased risk of dying during the following 12 months, even after adjusting for the STS mortality risk score (hazard ratio, 3.75; 95% confidence interval, 1.93-7.29; P<0.0001). The prognosis for patients with scores 26 to 50 did not differ significantly from those with higher scores (hazard ratio, 1.40; 95% confidence interval, 0.68-2.85; P=0.36).
Discussion
With the rapid development and increasing use of nonsurgical approaches for treatment of patients with severe AS, there is an urgent need to understand the impact of these innovative therapies on the short-and long-term quality of life of patients. Although improved long-term survival is a fundamental goal in the treatment of patients with severe AS, improved health status may be an equally important goal for the elderly, complex patients who are increasingly considered candidates for such therapies. Indeed, for many such patients, therapies that lead to better survival without improved quality of life may not be considered worthwhile. As such, it is critically important that studies of TAVR and its alternatives use a health status instrument that reliably and validly quantifies the spectrum of symptoms, functional status, and quality of life of patients with AS. 27 Previous studies have demonstrated that the KCCQ is a valid, sensitive, and prognostically relevant tool for quantifying health status and quality of life in patients with heart failure. [11] [12] [13] [14] [15] Because heart failure symptoms are the predominant clinical manifestations of patients with severe AS, 9, 10 we hypothesized that the KCCQ could serve as a valid disease-specific measure in such patients. In this study of nearly 1000 patients with severe symptomatic AS undergoing a variety of treatment approaches for their AS, we found that the KCCQ retains its previously documented psychometric properties. In addition, we found that among patients who were medically managed for their AS, KCCQ scores were strongly associated with long-term mortality, even after adjusting for the STS mortality risk score that integrates multiple prognostically important demographic and clinical characteristics, and thus could be used to help inform patients' expectations of the course of their disease.
Comparison With Prior Studies
The psychometric characteristics of the KCCQ in our study were comparable to those observed in the original KCCQ validation study, with similar internal consistency, reproducibility, responsiveness, and construct validity. 11 Importantly, the mean age of our population was 84 years versus 64 years in the original validation cohort of heart failure patients. Despite the older age of our population, the psychometric properties and interpretability of the KCCQ were similar to those observed in prior studies of heart failure patients. In addition to the original set of analyses, we also examined the sensitivity to change of the KCCQ and its ability to discriminate between different levels of change and found that the KCCQ also performed well in this regard. Of note, we did not include the self-efficacy domain in our analyses because we felt that the domain questions, which are designed to assess a patient's knowledge and confidence in managing his or her disease, would not be as applicable to patients with severe AS. There has been 1 study that examined the psychometric qualities of the Minnesota Living with Heart Failure Questionnaire in 50 patients undergoing valve surgery, 11 of whom had AS. 28 By evaluating the scale at baseline and after surgery, as compared with the SF-36, the authors found that this heart failure scale demonstrated acceptable internal consistency, construct validity, and responsiveness. Importantly, reliability, sensitivity to change, and prognostic associations were not assessed in this small sample of patients with mixed valvular heart disorders. The prognostic value of the KCCQ has been demonstrated previously among patients with heart failure. In a cohort of 1516 patients with recent acute myocardial infarction and heart failure or reduced left ventricular function, Soto et al 14 reported that patients with KCCQ overall summary scores <25 had a 2-fold increased hazard of death or rehospitalization during the following 11 months as compared with those with scores ≥75. Heidenreich et al 29 reported similar findings in an outpatient heart failure population. In the PARTNER trial population, we found that patients with severe AS and low KCCQ scores who were treated medically had nearly 4-fold higher risk of death in the following year as compared with those with higher KCCQ scores. The stronger association with mortality seen in our study most likely reflects both the older age of our patient population and the generally poorer prognosis of patients with severe symptomatic AS compared with the post-myocardial infarction heart failure population that has been studied previously. Of note, we did not include rehospitalization in our prognosis analyses, given the high mortality rate (50% dead by 1 year), and the high frequency of hospital admissions for procedures, such as balloon aortic valvuloplasty.
Limitations
Our study should be interpreted in the context of several potential limitations. First, virtually all patients in our study had advanced heart failure symptoms, as indicated by the high prevalence of NYHA class III or IV functional status at baseline. Thus, it is unclear whether our findings apply to patients with less severe symptomatic manifestations of heart failure, although there is no a priori reason to expect that the KCCQ would be less valid in these patients. It is important to note that many of the analyses were performed using data from 6-month follow-up after TAVR or AVR, at which time there was a much broader range of symptom levels and functional abilities, further underscoring the validity of the KCCQ in less symptomatic AS patients. Second, not all KCCQ domains had independent reference standards for the validity analyses, so some domains were compared against the same metrics (eg, the quality of life and social limitations domains were compared against the SF-12 mental components summary). Although we still observed strong correlations with the corresponding measures demonstrating acceptable validity of these domains, use of the more comprehensive SF-36 would have improved the specificity of our validity testing. Moreover, there is no gold standard for quantifying the impact of a disease on patients' perceptions of its impact on their function, symptoms, and quality of life. Finally, although we were able to assemble several appropriate patient groups in which to test the psychometric properties of the KCCQ in severe AS patients, these analytic populations were retrospectively constructed as secondary data analyses. As such, we were unable to examine every facet of its psychometric properties, such as face and content validity, which would need to be tested in a prospective manner.
Conclusions
On the basis of this study of patients from the PARTNER trial, the KCCQ seems to be a reliable, responsive, and a valid health status instrument for patients with AS. Importantly, the psychometric characteristics of the KCCQ were comparable to those observed in the original KCCQ validation study performed in post-myocardial infarction patients, despite differences in the age of the population and primary disease process. Given the importance of symptoms, functional status, and quality of life in elderly patients with severe AS, the KCCQ should be considered a highly relevant and meaningful outcome for both clinical trials and registry-based studies of TAVR. In addition, given its prognostic value, the KCCQ could also serve as an important tool in the clinical management of patients with severe AS. Future studies are necessary to determine whether the KCCQ can help guide the appropriate timing of valve intervention-both when symptoms and quality of life are impaired enough to intervene but before patients are too sick to benefit from valve replacement.
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